Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Quick facts
Marketed products
- Grazoprevir/Elbasvir · Infectious Disease / Virology
Grazoprevir and elbasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, respectively, blocking viral replication.
Phase 3 pipeline
- Lopinavir/ritonavir (drug) · Infectious Disease
Lopinavir/ritonavir is a combination protease inhibitor that blocks HIV protease, preventing viral replication by inhibiting the cleavage of viral polyproteins.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba portfolio CI brief
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba pipeline updates RSS
Frequently asked questions about Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
What are Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba's marketed drugs?
Top marketed products include Grazoprevir/Elbasvir.
What is Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba's pipeline?
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Lopinavir/ritonavir (drug).
Related
- Grazoprevir/Elbasvir · Infectious Disease / Virology
- Sector hub: All tracked pharma companies